Eric M Bank, M.D.
Investigator
Dr. Eric Bank is a board-certified medical oncologist and hematologist currently practicing at Sansum Clinic within the Ridley-Tree Cancer Center in Santa Barbara and Solvang, California. Since joining the clinic in 2019, he has provided comprehensive cancer care and has been actively involved in clinical research since 2018. In 2024, he was appointed Medical Director of the Ridley-Tree Cancer Center in Solvang, where he oversees clinical operations and supports the delivery of high-quality oncology services.
Dr. Bank earned his Bachelor of Arts from Yale University and his Doctor of Medicine from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at the University of California, Los Angeles (UCLA), followed by a fellowship in hematology and oncology at the UCLA-Olive View Medical Center.
Board certified in medical oncology, hematology, and internal medicine, Dr. Bank is committed to advancing cancer treatment through evidence-based care and clinical research, with a focus on improving patient outcomes and access to innovative therapies.
Clinical trials
- Clinical trial
Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB
FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.
Status: Open to Enrollment
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)
Status: Open to Enrollment
An Interventional Phase 3, Double-blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination with Chemotherapy Versus Pembrolizumab in Combination with Chemotherapy in Adult Participants with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status: Open to Enrollment
A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer
Status: Open to Enrollment
- Clinical trial
Neoadjuvant Breast Cancer OPERA-02
A Phase 3 Randomized, Double-Blind, Active-Controlled Study of Palazestrant With Ribociclib Versus Letrozole With Ribociclib for the First-Line Treatment of ER+, HER2- Advanced Breast Cancer (OPERA-02)
Status: Open to Enrollment